Faculty, Staff and Student Publications

Language

English

Publication Date

1-5-2026

Journal

Communications Biology

DOI

10.1038/s42003-025-09245-8

PMID

41490939

PMCID

PMC12769572

PubMedCentral® Posted Date

1-5-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Interactions among tumor, immune, and vascular niches play major roles in glioblastoma (GBM) malignancy and treatment responses. The composition and heterogeneity of extracellular core matrix proteins (CMPs) that mediate such interactions are not well understood. Here, we present an analysis of the clinical relevance of CMP expression in GBM at bulk, single-cell, and spatial anatomical resolution. We show that CMP enrichment is associated with worse patient survival, specific driver oncogenic alterations, mesenchymal state, pro-tumor immune infiltration, and immune checkpoint expression. Matrisome expression is enriched in vascular and leading edge/infiltrative niches that are known to harbor glioma stem cells. Finally, we identify a 17-gene CMP signature, termed Matrisome 17 (M17), which is a stronger prognostic factor compared to MGMT promoter methylation status as well as canonical subtypes, and importantly, may predict responses to PD1 blockade. Patient stratification based on matrisome profiles can contribute to the selection and optimization of treatment strategies.

Keywords

Glioblastoma, Humans, Prognosis, Brain Neoplasms, Gene Expression Regulation, Neoplastic, Tumor Microenvironment, Extracellular Matrix Proteins, Phenotype, Transcriptome, Biomarkers, Tumor, Gene Expression Profiling, CNS cancer, Genome informatics

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.